- Conditions
- Ischemic Stroke
- Interventions
- Not listed
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 7,238
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia
- Interventions
- Bifeprunox, Quetiapine
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 69
- States / cities
- Anaheim, California • Cerritos, California • Costa Mesa, California + 52 more
- Conditions
- Solid Tumor, Lymphoma
- Interventions
- TJ011133, Pembrolizumab, Rituximab
- Drug
- Lead sponsor
- I-Mab Biopharma US Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • New Haven, Connecticut + 9 more
- Conditions
- Lung Cancer
- Interventions
- radiation therapy
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 224
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 175 more
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma
- Interventions
- temozolomide, capecitabine
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 323
- States / cities
- Anaheim, California • Antioch, California • Baldwin Park, California + 221 more
- Conditions
- ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
- Interventions
- Impella CP® placement prior to reperfusion with Primary PCI
- Device
- Lead sponsor
- Abiomed Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 41 more
- Conditions
- Sickle Cell Disease
- Interventions
- Oxbryta® (voxelotor) 500-mg Tablets
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 12
- States / cities
- Farmington, Connecticut • Boston, Massachusetts • Detroit, Michigan + 6 more
- Conditions
- Multiple Myeloma
- Interventions
- CC-93269
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 5 more
- Conditions
- Glycogen Storage Disease Type II, Pompe Disease
- Interventions
- Not listed
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2034
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more
- Conditions
- Breast Neoplasms
- Interventions
- CC-486, Fulvestrant
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 5 more
- Conditions
- Atopic Dermatitis
- Interventions
- Placebo for Upadacitinib, Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 58
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 50 more
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
- Interventions
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2026
- U.S. locations
- 223
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 157 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- BGB 324 (before surgery), BGB 324 (after surgery)
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • Detroit, Michigan + 3 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Gefitinib, methotrexate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Palm Springs, California + 23 more
- Conditions
- Tibial Nonunions
- Interventions
- Surgical implantation of OP-1 device or autograft bone graft material
- Device
- Lead sponsor
- Olympus Biotech Corporation
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 1999
- U.S. locations
- 18
- States / cities
- Mesa, Arizona • Modesto, California • San Diego, California + 15 more
- Conditions
- Type 1 Diabetes
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 17
- States / cities
- Newport Beach, California • San Francisco, California • Miami, Florida + 13 more
- Conditions
- Pregnancy
- Interventions
- Mother receives voucher valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023), Mother receives voucher valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 4,700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2049
- U.S. locations
- 9
- States / cities
- Ann Arbor, Michigan • Detroit, Michigan • Ferndale, Michigan + 6 more
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3, THR-149 0.13mg, THR-149 0.13mg + aflibercept 2mg, aflibercept 2mg + THR-149 0.13mg, Aflibercept 2mg
- Drug
- Lead sponsor
- Oxurion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 32 more
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease
- Interventions
- Targeted Lung Denervation (TLD)
- Device
- Lead sponsor
- Nuvaira, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Jacksonville, Florida • Detroit, Michigan + 7 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec/insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 25
- States / cities
- Concord, California • Los Angeles, California • Montclair, California + 20 more
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, Cervical Cancer
- Interventions
- Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin, Itraconazole
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 952 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
- Conditions
- Cystic Fibrosis, Lung Infection, Pseudomonas Aeruginosa
- Interventions
- AZLI 75 mg three times daily (TID), Placebo three times daily (TID)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 26 more
- Conditions
- Advanced Cancer, Advanced Malignancies
- Interventions
- Cemiplimab, Hypofractionated radiotherapy, Cyclophosphamide, Docetaxel, Carboplatin, GM-CSF, Paclitaxel, Pemetrexed
- Drug · Radiation
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 40
- States / cities
- Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 31 more
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
- Interventions
- Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Surgical Procedure
- Drug · Procedure · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 81 more